SCIENCE

Involved in many disease pathologies, DUBs are attractive therapeutic targets

PLATFORM

World-leading DUB platform translating scientific advances into transformative therapies

PIPELINE

First-in-class small molecule DUB inhibitors developed in-house and with partners

USP30

Multiple in-house USP30 DUB inhibitor programs approaching clinical development

Mission Therapeutics

Mission Therapeutics is determined to make a positive impact on the lives of patients suffering from serious diseases including acute kidney injury (AKI), rare mitochondria diseases, neurodegeneration, and fibrosis by developing first-in-class therapeutics that inhibit disease-associated deubiquitylating enzymes (DUBs).

To hear our CEO discuss our technology, programs, recent progress and strategy, watch our Corporate Presentation.

2011

Founded

£73 million

Capital Investment

55

DUB targets explored

#1

In the DUB field

Commercializing expert research into

Dubs and Ubiquitin pathway

Mission Therapeutics’ strategy is to create value by advancing its pipeline programs through early clinical development, and preferentially with a patient selection strategy to enhance the probability of demonstrating early signs of efficacy. Selected programmes may be advanced in partnership with other pharmaceutical companies.

Mission Therapeutics © website by Instinctif Partners